Regeneron execs go on a whirlwind media tour after Trump takes COVID-19 antibody cocktail

Just days after Regeneron published early data on its antibody cocktail to treat COVID-19, the world found out the president of the U.S. was taking it.

What followed was a run-up for Regeneron shares, a series of shout-outs from President Donald Trump and a fair share of media appearances for the company's co-founders. The high-profile attention is a rare public relations bump that can’t be bought—and one the company seems at ease leveraging.